Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age
Brief Summary: Human Parainfluenza Virus Type 1 (HPIV1) is a leading cause of viral respiratory infections in children, the elderly, and those with compromised immune systems. HPIV1 is also the leading cause of viral croup in children under 6 years old. The purpose of this study is to determine the safety of and immune response to a HPIV1 vaccine, rHPIVI1 84/del170/942A, in 2 groups of adults and then in children who have been previously exposed to HPIV1. Once the safety of this vaccine has been established in these groups, an additional 2 groups of infants and children who have not been previously exposed to HPIV1 will be vaccinated. Naïve infants and children are the most vulnerable to naturally circulating HPIV1 and are the target population of this vaccine.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MEDI-534 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: MEDI-534 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: MEDI-534 | Intervention Type: BIOLOGICAL; Name: MEDI-534; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: MEDI-534; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MEDI-534; Assigned to Arm(s): 3
B: Arm Label: 1 and 2 - Adults; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 3A - Seropositive Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 3B - Seropositive Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 4A - Seronegative Infants and Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 4B - Seronegative Infants and Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 5A - Seronegative Infants and Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 5B - Seronegative Infants and Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine; Assigned to Arm(s): 1 and 2 - Adults, 3A - Seropositive Children, 4A - Seronegative Infants and Children, 5A - Seronegative Infants and Children | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3B - Seropositive Children, 4B - Seronegative Infants and Children, 5B - Seronegative Infants and Children
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Soap | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soap; Assigned to Arm(s): 1
D: Arm Label: RSV cps2 Vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV cps2 Vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Vaccine | Intervention Type: BIOLOGICAL; Name: RSV cps2 Vaccine; Assigned to Arm(s): RSV cps2 Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine; Assigned to Arm(s): Placebo

Answer: B